Skip to content
BioSupply Trends Quarterly logo
  • About Us
  • About Us
Subscribe
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
  • Home
  • News
    • All News
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Clinical Trials
    • COVID
    • Dermatology
    • Diagnostics
    • Disease Indications
    • FDA Updates
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Insurance Reimbursement
    • Medicare
    • Medicines
    • Mental Health
    • Therapeutics
    • Vaccines
    • Washington Report
    • Women’s Disorders
  • Industry Insight
    • All Industry Insight
    • Artificial Intelligence
    • Autoimmune Disorders
    • Biosimilars
    • Cancer
    • Chronic Illness
    • COVID
    • Dermatology
    • Disease Indications
    • Drug Safety
    • Gene Therapy
    • Immune Globulin
    • Immunodeficiencies
    • Influenza
    • Innovation & Discovery
    • Insurance Reimbursement
    • Manufacturing
    • Mental Health
    • Myths & Facts
    • Patient Safety
    • Plasma
    • Research & Development
    • Telehealth
    • Therapeutics
    • Vaccines
    • Women’s Disorders
  • Operations & Management
    • All Operations & Management
    • Artificial Intelligence
    • Drug Safety
    • Drug Shortages
    • Healthcare Management
    • Insurance Reimbursement
    • Reimbursement FAQs
    • Service & Safety
    • Staffing
  • Perspectives
    • All Perspectives
    • BSTQ&A
    • Leadership Corner
    • Patient Focus
    • Pharma5
    • Provider Focus
  • Resources
    • Available Resources
    • BioSupply Trends eNewsletter
  • Issues
    • Current Issue
    • Past Issues
  • Subscribe
  • About Us
BioSupply Trends Quarterly logo

CMS Launches Artificial Intelligence Health Outcomes Challenge

Illustration of robot hand and human hand touching fingers on a computer screen

CMS has launched the Artificial Intelligence Health Outcomes Challenge, a three-stage competition to accelerate artificial intelligence solutions that will potentially be used by CMS’s Innovation Center.

Artificial Intelligence and Big Data

BioSupply Trends Quarterly Fall 2018 Artificial Intelligence

Touted as the future of medicine, AI also has many ethical unknowns that will require discussion apace with progress.

← Previous
BioSupply Trends Quarterly logo
FFF Enterprises logo
  • Current Issue
  • Past Issues
  • Resources
  • Current Issue
  • Past Issues
  • Resources
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • About BSTQ
  • Subscribe to BSTQ
  • eNewsletter Opt-in
  • Contact Us
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
  • Advertiser Information
  • Media Kit
  • Editorial Calendar
  • Editorial Guidelines
Facebook-f Linkedin-in

FFF Enterprises.com | Privacy Statement | Terms of Use | California Consumer Privacy Act (CCPA) Opt-Out Icon

FFF Enterprises.com
Privacy Statement
Terms of Use
California Consumer Privacy Act (CCPA) Opt-Out Icon

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.